Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2023-06-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
关于第四届监事会第二十三次（临时）会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 23rd meeting of the 4th Supervisory Board of the company, including approval of a proposal for a specific issuance of A shares to certain investors, details about the issuance plan, pricing, quantity, lock-up period, use of proceeds, and related governance matters. It includes voting results and references to further shareholder approval. The content is focused on capital raising through a specific share issuance and related corporate governance decisions. It is not a full financial report, audit report, or earnings release, but rather a formal announcement of a capital/financing update and related supervisory board resolutions. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2023-06-21 Chinese
绿康生化2023年度向特定对象发行A股股票募集资金使用可行性分析报告
Capital/Financing Update Classification · 100% confidence The document is titled as a "2023年度向特定对象发行A股股票募集资金使用的可行性分析报告" which translates to "2023 Feasibility Analysis Report on the Use of Funds Raised by Private Placement of A Shares." It details the company's plan to raise capital through a specific stock issuance to certain investors, including the intended use of the funds, project descriptions, investment amounts, and expected benefits. The document extensively discusses the capital raising, investment projects, and financing needs. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is clearly a detailed capital/financing update related to a private placement and use of proceeds. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (over 14,000 characters) and detailed content confirm it is not merely an announcement but a substantive report on financing plans and feasibility.
2023-06-21 Chinese
关于本次向特定对象发行股票不存在直接或通过利益相关方向参与认购的投资者提供财务资助或补偿的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (438 characters) regarding a specific stock issuance event by the company 绿康生化股份有限公司. It states that the company does not provide financial assistance or compensation to investors involved in the specific share issuance. The content focuses on clarifying the terms of a capital raising event (specific share issuance) and contains no financial statements or detailed financial data. It is not a full report but an announcement related to capital structure changes. Therefore, it fits best under Capital/Financing Update (CAP).
2023-06-21 Chinese
关于向特定对象发行股票摊薄即期回报的风险提示及采取填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a specific issuance of shares to particular investors, focusing on the risk of dilution of immediate returns, the impact on financial indicators, and the measures to compensate for such dilution. It includes financial assumptions, risk warnings, necessity and rationality of the fundraising, commitments from directors and controlling shareholders, and procedural details. The document references regulatory guidelines from the China Securities Regulatory Commission and discusses the issuance of A-shares to specific investors. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is also not a call transcript, audit report, or legal proceeding. The content is centered on capital raising and financing activities, including share issuance and related risk disclosures. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length (7087 characters) and detailed financial impact analysis support this classification with high confidence.
2023-06-21 Chinese
募集资金管理制度（2023年6月修订）
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System'. It details the rules and procedures for managing funds raised through stock issuance, including storage, usage, supervision, and responsibilities. It references relevant laws and regulations such as the Company Law, Securities Law, and stock exchange rules. The content is a policy or governance document about how the company manages and supervises the use of raised capital, rather than a financial report, announcement, or presentation. It does not contain financial statements, earnings data, or voting results. It is a governance-related document outlining internal rules and procedures for capital management. Therefore, the most appropriate classification is Governance Information (CGR).
2023-06-21 Chinese
关于全资子公司完成工商变更登记的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding changes in the registration details of two wholly-owned subsidiaries of the company, including changes in registered capital, legal representatives, directors, and supervisors. It includes details of the updated business licenses and official registration information. There is no financial data, earnings information, or detailed report content. The document is a formal disclosure of management and structural changes at the subsidiary level, which aligns with announcements about changes in company management or board members. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length is short and it is not a report or financial statement, so it is not an Annual Report or Interim Report. It is not a regulatory filing or a report publication announcement since it contains substantive information about management changes.
2023-06-20 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.